Charles Schwab Investment Management Inc Glycomimetics Inc Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Glycomimetics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 22,361 shares of GLYC stock, worth $6,261. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,361
Previous 22,361
-0.0%
Holding current value
$6,261
Previous $52,000
28.85%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding GLYC
# of Institutions
81Shares Held
36.8MCall Options Held
969KPut Options Held
636K-
Bvf Inc San Francisco, CA9.54MShares$2.67 Million0.86% of portfolio
-
Artal Group S.A. Luxembourg, N48.59MShares$2.4 Million1.39% of portfolio
-
Nea Management Company, LLC Timonium, MD3.84MShares$1.07 Million0.81% of portfolio
-
Octagon Capital Advisors LP New York, NY3MShares$840,0001.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$773,3540.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $14.7M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...